Illumina

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, andcomplete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

1998: Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.

1999: In 1999, Illumina acquired Spyder Instruments (founded by Michal Lebl, Richard Houghten, and Jutta Eichler) for their technology of high-throughput synthesis.

2000: P1 reagents are now available for NextSeq 1000/NextSeq 2000 Systems, offering added flexibility to meet your project's needs Early research and development work was conducted in the Cambridge Chemistry Department until 2000, when Solexa’s corporate facilities were established at Chesterford Research Park.

2001: In 2001, the team’s research progress attracted £12 million in Series A funding, enabling it to build its management team.

2005: Solexa INC was formed in 2005 when Solexa Ltd reversed into Lynx Therapeutics of Hayward.

2006: The first Solexa sequencer, the Genome Analyzer, was launched in 2006 and gave scientists the power to sequence 1 gigabase (Gb) of data in a single run.

2007: On January 26, 2007, the Company completed the acquisition of Hayward based Solexa, Inc.

2009: In June 2009, Illumina announced the launch of their own Personal Full Genome Sequencing Service at a depth of 30X for $48,000 per genome, and a year later dropped the price to $19,500.

2010: Until 2010, Illumina sold only instruments that were labeled "for research use only"; in early 2010, Illumina obtained FDA approval for its BeadXpress system to be used in clinical tests.

2011: Illumina acquired Epicentre Biotechnologies, based in Madison, Wisconsin, on January 11, 2011.

2012: On January 25, 2012, Hoffmann-La Roche made an unsolicited bid to buy Illumina for $44.50 per share or about $5.7 billion.

2014: In 2014, the company announced a multi-million dollar product, HiSeqX Ten, that it forecast would provide large-scale whole-genome sequencing for $1,000/genome.

2015: In late 2015, Illumina spun off the company GRAIL, focused on blood testing for cancer tumors in the bloodstream.

2017: In 2017 the company had planned to raise $1 billion in its second round of financing, and received funding from Bill Gates and Jeff Bezos investing $100 million in series A funding, and with Illumina maintaining a 20% holding share in Grail.

2018: In November 2018, the company proposed the acquisition of Pacific Biosciences for $8.00 per share or around $1.2 billion in total.

2019: In December 2019, the Federal Trade Commission sued to block the acquisition.

2020: The proposed deal was abandoned on January 2, 2020, with Illumina paying Pacific a $98 million termination fee. In September 2020, Illumina announced a proposed cash and stock deal to acquire Grail for $8 billion.

2021: In March 2021, the FTC sued to block Illumina's $7.1 billion vertical merger with GRAIL. In July 2021, the European Commission opened an in-depth investigation into the GRAIL acquisition by Illumina.

To improve human health by unlocking the power of the genome.

Since our founding, we have never lost sight of the vision to transform human health. Our initial goal was to make it easy to decipher the genetic code in all of its variations.